c met inhibitor 1 — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T10655	c-Met inhibitor 1		c-Met/HGFR
	c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.		c-Met/HGFR
T5349	SCR-1481B1	c-Met inhibitor 2	VEGFR , c-Met/HGFR
	SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor		VEGFR , c-Met/HGFR
T4332	c-Kit-IN-1	PDGFR inhibitor 1,DCC-2618	c-Met/HGFR , c-Kit
	c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).		c-Met/HGFR , c-Kit
T8409	SYN1143	RON-IN-1,AMG-1	c-Met/HGFR
	SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively.		c-Met/HGFR
T15617	JNJ-38877618	OMO-1	c-Met/HGFR
	JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).		c-Met/HGFR
T11162	EGFR-IN-8		EGFR , c-Met/HGFR
	EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC.		EGFR , c-Met/HGFR
T13194	CSF1R-IN-2		c-Fms , c-Met/HGFR , Src
	CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).		c-Fms , c-Met/HGFR , Src
TQ0219	MK-8033		c-Met/HGFR
	MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).		c-Met/HGFR
T21312	Afatinib	Afatinib free base,BIBW 2992	EGFR , Autophagy
	Afatinib (BIBW 2992) is an irreversible inhibitor of EGFR family (EGFR-wt, EGFR-L858R, EGFR-L858R/T790M and HER2 with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM , respectively).		EGFR , Autophagy
T5164	Cabozantinib hydrochloride	XL184,Cabozantinib hydrochloride (849217-68-1(free base)),BMS-907351	VEGFR , FLT , c-Met/HGFR , TAM Receptor , c-Kit , ROR
	Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).		VEGFR , FLT , c-Met/HGFR , TAM Receptor , c-Kit , ROR
T1773	Afatinib Dimaleate	BIBW2992,Afatinib,BIBW 2992MA2,Afatinib (BIBW2992) Dimaleate	EGFR , HER , Autophagy
	Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic act...		EGFR , HER , Autophagy
T6260	AMG-208	AMG 208	P450 , c-Met/HGFR
	AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.		P450 , c-Met/HGFR
T63544	RIPK3-IN-1
	RIPK3-IN-1 is a type II RIPK3DFG-out site inhibitor (IC50: 9.1 nM) that inhibits RIPK1 (IC50: 5.5 μM) and RIPK2 (IC50>10 μM). RIPK3-IN-1 is a c-Met kinase inhibitor (IC50: 1.1 μM).
T8399	Crizotinib hydrochloride	PF-02341066 hydrochloride	c-Met/HGFR , ROS , ALK , Autophagy , ROS Kinase
	Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)		c-Met/HGFR , ROS , ALK , Autophagy , ROS Kinase
T5398	BMS 599626 2HCl (873837-23-1(HCl))	AC480 dihydrochloride	HER
	BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.		HER
T6039	TAK-285	TAK285,TAK 285	EGFR , MEK , HER , Aurora Kinase
	TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.		EGFR , MEK , HER , Aurora Kinase
T6380	AMG 900	AMG900,AMG-900	p38 MAPK , Tyrosine Kinases , Aurora Kinase
	AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM. It is >10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2. Phase 1.		p38 MAPK , Tyrosine Kinases , Aurora Kinase
T2668	JNK-IN-8	JNK Inhibitor XVI	JNK , c-Kit
	JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM). The selectivity is higher 10-fold than MNK2, Fms and no inhibition of Met, c-Kit, PDGFRβ in A375 cell line.		JNK , c-Kit
T6289	Dovitinib	TKI258,CHIR-258	VEGFR , FGFR , FLT , PDGFR , c-Kit
	Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs (IC50: 8-13 nM), less potent to E...		VEGFR , FGFR , FLT , PDGFR , c-Kit
T4349	Sitravatinib	MG516,MGCD516	Discoidin Domain Receptor (DDR) , VEGFR , FLT , Trk receptor , TAM Receptor , c-Kit , Ephrin Receptor
	Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.